Table 3.
Effect of zinc and placebo supplementation on plasma oxidative stress markers.
| Baseline | 6 months | p = (time × groupa) | |
|---|---|---|---|
| MDA + HAE (μmol/l) | |||
| Zinc suppl.b | 1.66 ± 0.34c | 1.35 ± 0.18 | 0.0002 |
| Placebo suppl.c | 1.70 ± 0.30 | 1.71 ± 0.35 | |
| 8-OHdG (ng/ml) | |||
| Zinc suppl. | 0.63 ± 0.16 | 0.50 ± 0.14 | 0.030 |
| Placebo suppl. | 0.66 ± 0.13 | 0.68 ± 0.13 | |
| Nitric oxide (μmol/l) | |||
| Zinc suppl. | 87.34 ± 8.08 | 79.01 ± 10.96 | 0.180 |
| Placebo suppl. | 89.43 ± 11.72 | 86.74 ± 9.28 |
Ref (5).
ap Value for change in groups over time. Multivariate repeated measures analyses were used to examine measures over time. bZinc (n = 13) or placebo (n = 11) supplemented subjects. cValues represent mean ± SD. There were no significant differences (t-test) in oxidative stress markers between the two groups at baseline.